blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3768830

EP3768830 - CANCER THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.12.2023
Database last updated on 14.03.2026
FormerThe patent has been granted
Status updated on  23.12.2022
FormerGrant of patent is intended
Status updated on  21.09.2022
FormerExamination is in progress
Status updated on  17.12.2021
FormerRequest for examination was made
Status updated on  25.12.2020
FormerThe international publication has been made
Status updated on  28.09.2019
Formerunknown
Status updated on  02.04.2019
Most recent event   Tooltip26.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 28.01.2026  [2026/05]
Applicant(s)For all designated states
Valo Therapeutics Oy
Cultivator 1 Viikinkaari 6
00790 Helsinki / FI
[2021/04]
Inventor(s)01 / RANKI, Tuuli
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
02 / PESONEN, Sari
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
03 / PRIHA, Petri
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
04 / YLÖSMÄKI, Erkko
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
05 / CERULLO, Vincenzo
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
06 / MARTINS, Beatriz
Valo Therapeutics Oy
Cultivator 1
Viikinkaari 6
00790 Helsinki / FI
 [2021/04]
Representative(s)Myint, Julie Marie
Symbiosis IP Limited
Unit 5C
Sbarc l Spark Building
Maindy Road
Cardiff CF24 4HQ / GB
[N/P]
Former [2021/04]Myint, Julie Marie
Symbiosis IP Limited
Cardiff MediCentre
Heath Park
Cardiff CF14 4UJ / GB
Application number, filing date19712179.119.03.2019
[2021/04]
WO2019EP56770
Priority number, dateGB2018000446821.03.2018         Original published format: GB 201804468
GB2018001486613.09.2018         Original published format: GB 201814866
[2021/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019179979
Date:26.09.2019
Language:EN
[2019/39]
Type: A1 Application with search report 
No.:EP3768830
Date:27.01.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 26.09.2019 takes the place of the publication of the European patent application.
[2021/04]
Type: B1 Patent specification 
No.:EP3768830
Date:25.01.2023
Language:EN
[2023/04]
Search report(s)International search report - published on:EP26.09.2019
ClassificationIPC:C12N7/00, C12N15/86, A61K39/00, A61K35/761
[2021/04]
CPC:
C12N7/00 (EP,CN,KR,US); A61K35/761 (EP,CN,KR); C12N15/86 (EP,CN,KR,US);
A61K39/00 (EP,US); A61K39/0011 (EP,CN,US); A61K39/001186 (EP,CN,KR,US);
A61K39/001188 (EP,CN,KR,US); A61K45/06 (CN,KR); A61P35/00 (EP,CN,KR,US);
C07K14/70575 (CN,KR); C07K14/70578 (CN,KR); C07K16/2818 (CN,KR,US);
C07K16/2827 (CN,KR,US); A61K2039/505 (CN,KR); A61K2039/525 (CN,KR);
A61K2039/6031 (EP,CN,KR); C12N2710/10332 (EP,CN,KR,US); C12N2710/10343 (EP,CN,KR,US) (-)
C-Set:
A61K35/761, A61K2300/00 (CN);
A61K39/001186, A61K2300/00 (CN);
A61K39/001188, A61K2300/00 (CN);
A61K39/0011, A61K2300/00 (CN)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/04]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:KREBSTHERAPIE[2021/04]
English:CANCER THERAPY[2021/04]
French:THÉRAPIE ANTICANCÉREUSE[2021/04]
Entry into regional phase23.09.2020National basic fee paid 
23.09.2020Designation fee(s) paid 
23.09.2020Examination fee paid 
Examination procedure05.07.2019Request for preliminary examination filed
International Preliminary Examining Authority: EP
23.09.2020Examination requested  [2021/04]
23.09.2020Date on which the examining division has become responsible
19.03.2021Amendment by applicant (claims and/or description)
16.12.2021Despatch of a communication from the examining division (Time limit: M02)
20.12.2021Reply to a communication from the examining division
22.09.2022Communication of intention to grant the patent
20.12.2022Fee for grant paid
20.12.2022Fee for publishing/printing paid
20.12.2022Receipt of the translation of the claim(s)
Opposition(s)26.10.2023No opposition filed within time limit [2024/01]
Fees paidRenewal fee
15.03.2021Renewal fee patent year 03
10.02.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY19.03.2019
HU19.03.2019
AT25.01.2023
BG25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SI25.01.2023
SK25.01.2023
SM25.01.2023
TR25.01.2023
IE19.03.2023
LU19.03.2023
BE31.03.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
[2026/05]
Former [2025/39]CY19.03.2019
HU19.03.2019
AT25.01.2023
BG25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SI25.01.2023
SK25.01.2023
SM25.01.2023
IE19.03.2023
LU19.03.2023
BE31.03.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2025/36]CY19.03.2019
AT25.01.2023
BG25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SI25.01.2023
SK25.01.2023
SM25.01.2023
IE19.03.2023
LU19.03.2023
BE31.03.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2024/51]AT25.01.2023
BG25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SI25.01.2023
SK25.01.2023
SM25.01.2023
IE19.03.2023
LU19.03.2023
BE31.03.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2024/11]AT25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SI25.01.2023
SK25.01.2023
SM25.01.2023
IE19.03.2023
LU19.03.2023
BE31.03.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2024/08]AT25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SK25.01.2023
SM25.01.2023
IE19.03.2023
LU19.03.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2024/02]AT25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SK25.01.2023
SM25.01.2023
LU19.03.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/50]AT25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SK25.01.2023
SM25.01.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/49]AT25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SM25.01.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/48]AT25.01.2023
EE25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RS25.01.2023
SM25.01.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/46]AT25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RS25.01.2023
SM25.01.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/39]AT25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RS25.01.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/38]AT25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RS25.01.2023
GR26.04.2023
PT25.05.2023
Former [2023/37]AT25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
RS25.01.2023
GR26.04.2023
PT25.05.2023
Former [2023/36]AT25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
RS25.01.2023
PT25.05.2023
Former [2023/35]AT25.01.2023
HR25.01.2023
LT25.01.2023
RS25.01.2023
PT25.05.2023
Former [2023/34]LT25.01.2023
RS25.01.2023
PT25.05.2023
Former [2023/33]LT25.01.2023
Cited inInternational search[Y] WO2015177098  (HELSINGIN YLIOPISTO et al.) [Y] 1-25 * figure -; example -; claim - *
 [Y] WO0052045  (SAN RAFFAELE CENTRO FOND et al.) [Y] 1-25 * example -; claim - *
 [Y] US2008175871  (BRADWELL ARTHUR RANDALL et al.) [Y] 1-25 * paragraph [0074] - paragraph [0077]; sequence 4 *
 [XP]   YLOSMAKI E ET AL: "Abstract B123: Local treatment with PeptiCRAd-1, a novel cancer immunotherapy approach, mediates a systemic antitumour CD8+ T-cell response and infiltration of CD8+ and CD4+ T-cells into distant untreated tumors in a clinically relevant humanized mouse model", CANCER IMMUNOLOGY RESEARCH, vol. 7, no. Suppl. 2, B123, 1 February 2019 (2019-02-01), XP055584985, Retrieved from the Internet [retrieved on 20190502] [XP] 1-25 * the whole document *

DOI:   http://dx.doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-B123
 [Y]   CAPASSO C ET AL: "Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma", ONCOIMMUNOLOGY, vol. 5, no. 4, 29 October 2015 (2015-10-29), pages e1105429, XP055271942, DOI: 10.1080/2162402X.2015.1105429 [Y] 1-25 * abstract, results; discussion; *

DOI:   http://dx.doi.org/10.1080/2162402X.2015.1105429
 [Y]   KAKIMI K ET AL: "A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 129, no. 12, 15 December 2011 (2011-12-15), pages 2836 - 2846, XP002737832, ISSN: 0020-7136, [retrieved on 20110329], DOI: 10.1002/IJC.25955 [Y] 1-25 * abstract, materials and methods, results, discussion; *

DOI:   http://dx.doi.org/10.1002/ijc.25955
 [Y]   ADAMS S ET AL: "Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant", THE JOURNAL OF IMMUNOLOGY, vol. 181, no. 1, 19 June 2008 (2008-06-19), US, pages 776 - 784, XP055585098, ISSN: 0022-1767, DOI: 10.4049/jimmunol.181.1.776 [Y] 1-25 * abstract, materials and methods, results, figure 4; *

DOI:   http://dx.doi.org/10.4049/jimmunol.181.1.776
 [Y]   BAREN VAN N ET AL: "TUMORAL AND IMMUNOLOGIC RESPONSE AFTER VACCINATION OF MELANOMA PATIENTS WITH AN ALVAC VIRUS ENCODING MAGE ANTIGENS RECOGNIZED BY T CELLS", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 35, 10 December 2005 (2005-12-10), pages 9008 - 9021, XP009075846, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.08.375 [Y] 1-25 * abstract; results; discussion; *

DOI:   http://dx.doi.org/10.1200/JCO.2005.08.375
 [A]   CAPASSO C ET AL: "A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma", ONCOIMMUNOLOGY, vol. 6, no. 9, 11 May 2017 (2017-05-11), pages e1319028, XP055560179, DOI: 10.1080/2162402X.2017.1319028 [A] 1-25 * abstract, results, discussion; *

DOI:   http://dx.doi.org/10.1080/2162402X.2017.1319028
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.